A CLINICAL TRIAL TO STUDY THE EFFECT OF THE DRUG ELATHY CHOORANAM IN PATIENTS HAVING PEPTIC ULCER

EVALUATION OF ERIGUNMATHIRKU ELATHY CHOORANAM FOR ERIGUNMAM (PEPTIC ULCER DISEASE) - AN OPEN CLINICAL STUDY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016564

Enrollment

Registered

2018-12-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K20-K31- Diseases of esophagus, stomach and duodenum

Interventions

Intervention1: ERIGUNMATHIRKU ELATHY CHOORANAM: ERIGUNMATHIRKU ELATHY CHOORANAM IS ADMINISTERED ORALLY AT THE DOSE OF 1 GRAM TWICE A DAY ALONG WITH HONEY AS AN ADJUVANT FOR 48 DAYS Control Interventio

Eligibility

Inclusion criteria

Inclusion criteria: DURATION OF ILLNESS NOT MORE THAN 10 YEARS BURNING EPIGASTRIC PAIN ABDOMINAL BLOATING ANOREXIA ALTERED BOWEL HABITS NAUSEA VOMITING

Exclusion criteria

Exclusion criteria: PYLORIC STENOSIS CARCINOMA STOMACH ACUTE ABDOMINAL COLIC GASTRIC PERFORATION GASTRIC OBSTRUCTION CHOLELITHIASIS PANCREATITIS APPENDICTIS RENAL COLIC

Design outcomes

Primary

Measure	Time frame
THE OUTCOME OF THE TREATMENT IS MAINLY ASSESSED BY REDUCTION IN CLINICAL SYMPTOMS MEASURED BY ULCER INDEX SCORES BEFORE AND AFTER THE TREATMENTTimepoint: 48 DAYS	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDR LAVANYA A

GOVERNMENT SIDDHA MEDICAL COLLEGE ARUMBAKKAM CHENNAI

Mmsankar2000@gmail.com9445716802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026